Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

@article{Segal2008RepeatedSI,
  title={Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study},
  author={B. Segal and Cris S. Constantinescu and Aparna Raychaudhuri and Lilianne Kim and Rosanne Fidelus-Gort and Lloyd H. Kasper},
  journal={The Lancet Neurology},
  year={2008},
  volume={7},
  pages={796-804}
}
BACKGROUND Repeated subcutaneous injections of a monoclonal antibody against the p40 subunit of interleukins 12 and 23, ustekinumab, were used to treat patients with relapsing-remitting multiple sclerosis (RRMS) to assess the drug's safety, efficacy, and pharmacokinetics. METHODS In this phase II, multicentre, randomised, double-blind, placebo-controlled study, 249 patients with RRMS, aged 18-65 years, were eligible to be assigned equally (by a central randomisation procedure based on study… Expand
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
TLDR
The paper under review is a Phase II clinical trial of ustekinumab, an anti-IL-12/23p40 antibody for treatment of multiple sclerosis, which found no clinical or radiologic improvement in any treatment group compared with placebo controls. Expand
A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing–remitting or secondary progressive multiple sclerosis
TLDR
The magnitude of ABT-874 efficacy was less than that observed with other agents currently in development for MS treatment, and anti-IL-12/23 monotherapy does not appear to warrant further testing as monotherapy treatment for MS. Expand
Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study
TLDR
This proof-of-concept study provides the first evidence that blocking IL-17A with an antibody may reduce MRI lesion activity in MS. Expand
Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort
TLDR
Subcutaneous ustekinumab is effective and safe in a high proportion of patients with CD that were resistant to conventional immunosuppressant and antitumor necrosis factor drugs. Expand
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
TLDR
The safety profile of continued ustekinumab exposure through up to 3 years is favorable and consistent with previous short-term reports. Expand
Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement
TLDR
Ustekinumab is easy to use, has a comfortable therapeutic regimen, improves quality of life in patients, and thus appears to be an attractive biological treatment that is adapted and accepted by patients with moderate to severe psoriasis. Expand
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes
  • J. Lycke
  • Medicine
  • Therapeutic advances in neurological disorders
  • 2015
TLDR
Monoclonal antibody therapies for relapsing-remitting multiple sclerosis target immune cells or other molecules involved in pathogenic pathways with extraordinary specificity, and each mAb treatment has a unique administration schedule. Expand
Treating multiple sclerosis with monoclonal antibodies: a 2010 update
  • M. Buttmann
  • Medicine
  • Expert review of neurotherapeutics
  • 2010
TLDR
The natalizumab section of the article centers around progressive multifocal leukoencephalopathy (PML), and discusses PML risk in relation to treatment duration, bioassays for individual risk prediction, the concept of drug holidays, clinical course and treatment of PML, as well as safety-related regulatory actions. Expand
Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials
TLDR
A meta-analysis to compare rates of adverse events (AEs) in randomized controlled trials (RCTs) of UST for all indications found that UST was not associated with an increase in short-term risk of AEs. Expand
Monoclonal antibody therapy in multiple sclerosis
TLDR
The appearance of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated MS patients, as well as in patients with lymphoma, lupus and rheumatoid arthritis treated with rituximab, and autoimmune-type complications in alemtuzumab - treated MS patients underlines the fact that extended efficacy comes with significant clinical risks. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 49 REFERENCES
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
TLDR
Ustekinumab seems to be efficacious for the treatment of moderate-to-severe psoriasis; dosing every 12 weeks maintains efficacy for at least a year in most patients. Expand
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
TLDR
Subcutaneous interferon β-1a is an effective treatment for relapsing/remitting MS in terms of relapse rate, defined disability, and all MRI outcome measures in a dose-related manner, and it is well tolerated. Expand
A phase I trial of an interleukin‐12/23 monoclonal antibody in relapsing multiple sclerosis
TLDR
Single subcutaneous administrations of IL‐12/23 mAb in this first study of relapsing MS were generally well tolerated, and safety of the agent will need to be tested in a study of longer duration and involving a larger cohort of subjects. Expand
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
TLDR
A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks and provides evidence of B-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis. Expand
Treatment of multiple sclerosis with gamma interferon
TLDR
Results show that systemic administration of gamma interferon has pronounced effects on cellular immunity in MS and on disease activity within the CNS, suggesting that the attacks induced during treatment were immunologically mediated. Expand
A controlled trial of natalizumab for relapsing multiple sclerosis.
TLDR
In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis. Expand
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
TLDR
It is demonstrated that copolymer 1 treatment can significantly and beneficially alter the course of relapsing-remitting multiple sclerosis in a well-tolerated fashion. Expand
Suppression of Ongoing Disease in a Nonhuman Primate Model of Multiple Sclerosis by a Human-Anti-Human IL-12p40 Antibody1
TLDR
Whether ongoing disease in a nonhuman primate model of multiple sclerosis can be suppressed with a new human IgG1κ Ab against human IL-12p40 is examined and changes in the total T2 lesion volume and T2 relaxation times were significantly suppressed. Expand
Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand.
TLDR
It is found that interleukin 12 (IL- 12) was responsible for raised IFN-gamma secretion in MS as anti-IL-12 antibodies reversed raised anti-CD3-induced IFN -gamma in MS patients to normal levels and provided a basis for immune intervention in the disease. Expand
Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.
TLDR
Treatment with anti-IL-23p19 effectively inhibited multiple inflammatory pathways that are critical for driving CNS autoimmune inflammation and prevented subsequent disease relapse. Expand
...
1
2
3
4
5
...